While a new treatment for psoriasis could be of value for these patients, this is probably not the type of breakthrough that GSK originally envisioned when they did this deal.
Walsh says this was the first efficacy data for Raptiva, and so long as the problem in the rheumatoid-arthritis study was effectiveness, not safety, it shouldn't worry investors focused on Raptiva's near-term approval to treat psoriasis.